PLEKHA6

Across TCGA pan-cancer cohorts, PLEKHA6 RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated PLEKHA6 data layer compared with 5 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher PLEKHA6 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated PLEKHA6 expression acts as an unfavorable survival marker, although some lineages such as DLBC and ACC show a favorable association.

DLBC, LUAD, and LUSC are the cancer types where PLEKHA6 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Tertile	All	1.000	0.444	.003	58	view →
LUAD	DFS	Quartile	II,III,IV	0.570	0.785	<.001	55	view →
LUSC	DFS	Quartile	All	0.269	0.497	<.001	54	view →
ACC	DFS	Median	All	0.762	0.421	<.001	42	view →
SKCM	OS	Tertile	III,IV	0.601	0.808	.001	35	view →
BLCA	OS	Quartile	All	0.612	0.385	.001	33	view →
KIRC	DFS	Tertile	All	0.819	0.490	<.001	30	view →
ESCA	OS	Median	All	0.617	1.000	.009	27	view →
READ	DFS	Tertile	II,III,IV	0.645	0.875	.003	26	view →
LAML	DFS	Median	All	0.262	0.493	.003	26	view →
CHOL	DFS	Quartile	All	0.153	0.635	.001	18	view →
PRAD	DFS	Median	All	0.957	0.909	.012	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

PLEKHA6–DLBC (DFS)

Open the DLBC breakdown →